We are live on ! Find out more
ACXP icon

Acurx Pharmaceuticals
ACXP

14 hedge funds and large institutions have $4.66M invested in Acurx Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

226% more capital invested

Capital invested by funds: $1.43M → $4.66M (+$3.23M)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

17% more funds holding

Funds holding: 12 → 14 (+2)

0.49% more ownership

Funds ownership: 0.18% → 0.67% (+0.49%)

Holders
14
Holders Change
+2
Holders Change %
+16.67%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
1
Closed
2
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$3.99M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$242K
3
Millennium Management
Millennium Management
New York
+$177K
4
Mariner
Mariner
Kansas
+$59.9K
5
UBS Group
UBS Group
Switzerland
+$11.4K

Top Sellers

Rank Fund Capital Flow
1
CWM
Castle Wealth Management
Florida
-$49K
2
PFGIA
Patriot Financial Group Insurance Agency
Massachusetts
-$37K
3
BlackRock
BlackRock
New York
-$1.65K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$3.2M +$3.99M +53,300 New
DAM
2
Draper Asset Management
New York
$798K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$228K +$242K +3,235 +561%
Millennium Management
4
Millennium Management
New York
$142K +$177K +2,369 New
TWC
5
TD Waterhouse Canada
Ontario, Canada
$90.9K – – –
Mariner
6
Mariner
Kansas
$48K +$59.9K +800 New
BlackRock
7
BlackRock
New York
$47K -$1.65K -22 -3%
Osaic Holdings
8
Osaic Holdings
Arizona
$36K +$3.74K +50 +9%
TAM
9
Tocqueville Asset Management
New York
$30K – – –
SFA
10
Semmax Financial Advisors
North Carolina
$17K – – –
UBS Group
11
UBS Group
Switzerland
$12K +$11.4K +152 +292%
TRCT
12
Tower Research Capital (TRC)
New York
$9K +$4.27K +57 +65%
CWM
13
Castle Wealth Management
Florida
– -$49K -650 Closed
PFGIA
14
Patriot Financial Group Insurance Agency
Massachusetts
– -$37K -488 Closed
Wells Fargo
15
Wells Fargo
California
– +$150 +2 +200%
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
– +$299 +4 New

ACXP Hedge Fund Activity: Q3 2022 in Review

14 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q3 2022, worth a combined $4.66M — up 226% from $1.43M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ACXP positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $3.99M. The largest seller was Castle Wealth Management, exiting entirely with an estimated $49K sold.

  • 14 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q3 2022, up from 12 in Q2 2022.
  • Funds reported $4.66M of Acurx Pharmaceuticals stock for Q3 2022, up 226% quarter-over-quarter.
  • 4 funds opened new Acurx Pharmaceuticals positions in Q3 2022 and 2 closed out, a net change of +2 holders.
  • The largest Acurx Pharmaceuticals buyer in Q3 2022 was Armistice Capital, an estimated $3.99M added.
  • The largest Acurx Pharmaceuticals seller in Q3 2022 was Castle Wealth Management, an estimated $49K sold.

Based on aggregated 13F filings for Q3 2022.